Arena Pharmaceuticals Inc
ARNA
ARNA 종목은 2022년 3월 10일에 상장 폐지됐어요.
소개: Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
직원 수: 448
뉴스
ARNA에 대한 최신 뉴스 기사를 아직 받지 못했어요.